Cetuximab promotes RSL3-induced ferroptosis by suppressing the Nrf2/HO-1 signalling pathway in KRAS mutant colorectal cancer

Abstract Cetuximab is approved for the treatment of metastatic colorectal cancer (mCRC) with RAS wild-type. Nevertheless, the prognosis remains poor and the effectiveness of cetuximab is limited in KRAS mutant mCRC. Recently, emerging evidence has shown that ferroptosis, a newly discovered form of n...

Full description

Saved in:
Bibliographic Details
Main Authors: Jiawen Yang, Jiajie Mo, Juji Dai, Chenqiao Ye, Wei Cen, Xuzhi Zheng, Lei Jiang, Lechi Ye
Format: article
Language:EN
Published: Nature Publishing Group 2021
Subjects:
Online Access:https://doaj.org/article/c2181e41f0cc462294e76d04f119e6f0
Tags: Add Tag
No Tags, Be the first to tag this record!